Abstract
Objective: The aim of this study was to investigate whether the addition of ribavirin (RIBA) to interferon-α (IFN-α) therapy increases the risk of developing thyroid autoimmunity and/or dysfunction. Design and Methods: The study group (group A) included 72 patients undergoing treatment with IFN-α (3-6 million units three times weekly) plus RIBA (1.0-1.2g/day) for chronic hepatitis C (CHC), as first line therapy (30 cases) or as a second therapeutic attempt after a previous ineffective IFN-α treatment (42 cases). The control group (group B) encompassed 75 age- and sex-matched patients affected by CHC, undergoing treatment with IFN-α alone as first line therapy (35 cases) or as a second therapeutic attempt (40 cases). Thyroid autoimmunity and function were retrospectively evaluated on frozen aliquots, drawn before, after 6 months, and at the end of the antiviral treatment. In patients receiving two antiviral treatments (42 cases in group A and 40 cases in group B) thyroid parameters were also assayed on serum samples drawn before and at the end of the first IFN-α therapy. Results: Thyroid autoimmunity rate (17/72 for group A and 17/75 for group B) as well as anti-thyroglobulin antibodies (TgAb) and anti-thyroid peroxidase antibodies (TPOAb) serum levels were comparable between the two groups. Similarly, in patients undergoing two consecutive antiviral treatments (42 cases in group A and 40 cases in group B) the percentage of positivity for thyroid autoantibodies did not change significantly from the first to the second therapeutic schedules in both groups, with no significant increase of median TgAb and TPOAb levels. By the same token, all but one patient negative for thyroid autoantibodies at the end of the first treatment remained so also during the subsequent treatment. In group A patients, the rate of hypothyroidism (11/72) was significantly higher than that observed in group B (3/75). Similarly, in patients undergoing two consecutive antiviral treatments the percentage of hypothyroidism increased significantly from the first to the second therapeutic schedule in group A (from 4.8% to 19.0% P
| Original language | English |
|---|---|
| Pages (from-to) | 743-749 |
| Number of pages | 7 |
| Journal | European Journal of Endocrinology |
| Volume | 146 |
| Issue number | 6 |
| Publication status | Published - 2002 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
Cite this
The addition of ribavirin to interferon-α therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. / Carella, Carlo; Mazziotti, Gherardo; Morisco, Filomena; Rotondi, Mario; Cioffi, Michele; Tuccillo, Concetta; Sorvillo, Francesca; Caporaso, Nicola; Amato, Giovanni.
In: European Journal of Endocrinology, Vol. 146, No. 6, 2002, p. 743-749.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The addition of ribavirin to interferon-α therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism
AU - Carella, Carlo
AU - Mazziotti, Gherardo
AU - Morisco, Filomena
AU - Rotondi, Mario
AU - Cioffi, Michele
AU - Tuccillo, Concetta
AU - Sorvillo, Francesca
AU - Caporaso, Nicola
AU - Amato, Giovanni
PY - 2002
Y1 - 2002
N2 - Objective: The aim of this study was to investigate whether the addition of ribavirin (RIBA) to interferon-α (IFN-α) therapy increases the risk of developing thyroid autoimmunity and/or dysfunction. Design and Methods: The study group (group A) included 72 patients undergoing treatment with IFN-α (3-6 million units three times weekly) plus RIBA (1.0-1.2g/day) for chronic hepatitis C (CHC), as first line therapy (30 cases) or as a second therapeutic attempt after a previous ineffective IFN-α treatment (42 cases). The control group (group B) encompassed 75 age- and sex-matched patients affected by CHC, undergoing treatment with IFN-α alone as first line therapy (35 cases) or as a second therapeutic attempt (40 cases). Thyroid autoimmunity and function were retrospectively evaluated on frozen aliquots, drawn before, after 6 months, and at the end of the antiviral treatment. In patients receiving two antiviral treatments (42 cases in group A and 40 cases in group B) thyroid parameters were also assayed on serum samples drawn before and at the end of the first IFN-α therapy. Results: Thyroid autoimmunity rate (17/72 for group A and 17/75 for group B) as well as anti-thyroglobulin antibodies (TgAb) and anti-thyroid peroxidase antibodies (TPOAb) serum levels were comparable between the two groups. Similarly, in patients undergoing two consecutive antiviral treatments (42 cases in group A and 40 cases in group B) the percentage of positivity for thyroid autoantibodies did not change significantly from the first to the second therapeutic schedules in both groups, with no significant increase of median TgAb and TPOAb levels. By the same token, all but one patient negative for thyroid autoantibodies at the end of the first treatment remained so also during the subsequent treatment. In group A patients, the rate of hypothyroidism (11/72) was significantly higher than that observed in group B (3/75). Similarly, in patients undergoing two consecutive antiviral treatments the percentage of hypothyroidism increased significantly from the first to the second therapeutic schedule in group A (from 4.8% to 19.0% P
AB - Objective: The aim of this study was to investigate whether the addition of ribavirin (RIBA) to interferon-α (IFN-α) therapy increases the risk of developing thyroid autoimmunity and/or dysfunction. Design and Methods: The study group (group A) included 72 patients undergoing treatment with IFN-α (3-6 million units three times weekly) plus RIBA (1.0-1.2g/day) for chronic hepatitis C (CHC), as first line therapy (30 cases) or as a second therapeutic attempt after a previous ineffective IFN-α treatment (42 cases). The control group (group B) encompassed 75 age- and sex-matched patients affected by CHC, undergoing treatment with IFN-α alone as first line therapy (35 cases) or as a second therapeutic attempt (40 cases). Thyroid autoimmunity and function were retrospectively evaluated on frozen aliquots, drawn before, after 6 months, and at the end of the antiviral treatment. In patients receiving two antiviral treatments (42 cases in group A and 40 cases in group B) thyroid parameters were also assayed on serum samples drawn before and at the end of the first IFN-α therapy. Results: Thyroid autoimmunity rate (17/72 for group A and 17/75 for group B) as well as anti-thyroglobulin antibodies (TgAb) and anti-thyroid peroxidase antibodies (TPOAb) serum levels were comparable between the two groups. Similarly, in patients undergoing two consecutive antiviral treatments (42 cases in group A and 40 cases in group B) the percentage of positivity for thyroid autoantibodies did not change significantly from the first to the second therapeutic schedules in both groups, with no significant increase of median TgAb and TPOAb levels. By the same token, all but one patient negative for thyroid autoantibodies at the end of the first treatment remained so also during the subsequent treatment. In group A patients, the rate of hypothyroidism (11/72) was significantly higher than that observed in group B (3/75). Similarly, in patients undergoing two consecutive antiviral treatments the percentage of hypothyroidism increased significantly from the first to the second therapeutic schedule in group A (from 4.8% to 19.0% P
UR - http://www.scopus.com/inward/record.url?scp=0036299570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036299570&partnerID=8YFLogxK
M3 - Article
C2 - 12039693
AN - SCOPUS:0036299570
VL - 146
SP - 743
EP - 749
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
SN - 0804-4643
IS - 6
ER -